138 related articles for article (PubMed ID: 9134025)
1. Use of cryopreserved lymphocytes for assessment of the immunological effects of interferon therapy in renal cell carcinoma patients.
Sobota V; Bubeník J; Indrová M; Vlk V; Jakoubková J
J Immunol Methods; 1997 Apr; 203(1):1-10. PubMed ID: 9134025
[TBL] [Abstract][Full Text] [Related]
2. IFN-alpha therapy of renal-cell carcinoma - defect of lymphocyte sensitivity to mitogenic and activating cytokine signals in patients not-responding to therapy.
Indrova M; Bubenik J; Jakoubkova J; Sobota V; Helmichova E; Simova J
Int J Oncol; 1995 Sep; 7(3):523-6. PubMed ID: 21552869
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12.
Ulchaker J; Panuto J; Rayman P; Novick A; Elson P; Tubbs R; Finke JH; Bukowski RM
J Immunother; 1999 Jan; 22(1):71-9. PubMed ID: 9924702
[TBL] [Abstract][Full Text] [Related]
5. Immune inhibitory effects of renal cell carcinoma extract on lectin and alloantigen-induced peripheral blood and tumor infiltrating lymphocyte blastogenesis.
Shabtai M; Ye H; Kono K; Takayam T; Terashima K; Tsukuda K; Frischer Z; Waltzer WC; Malinowski K
Urol Oncol; 2003; 21(1):27-32. PubMed ID: 12684124
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
[TBL] [Abstract][Full Text] [Related]
7. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
[TBL] [Abstract][Full Text] [Related]
8. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
[TBL] [Abstract][Full Text] [Related]
9. [Immunological assessment of tumour infiltrating lymphocyte subsets in renal cell carcinoma patients. An analysis of immunological reaction to immuno-competent lymphocytes by interferon-gamma].
Ohnishi T
Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):216-24. PubMed ID: 1904117
[TBL] [Abstract][Full Text] [Related]
10. [Lysis of autologous tumor cells by peripheral blood lymphocytes treated with IFN-alpha in patients with renal cell carcinoma].
Kubota S
Nihon Hinyokika Gakkai Zasshi; 1992 Nov; 83(11):1781-8. PubMed ID: 1479751
[TBL] [Abstract][Full Text] [Related]
11. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic in vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy. Effects of activation with recombinant interleukin-2.
Feruglio C; Zambello R; Trentin L; Bulian P; Franceschi T; Cetto GL; Semenzato G
Cancer; 1992 May; 69(10):2525-31. PubMed ID: 1568175
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer.
Elsässer-Beile U; Rindsfüser M; Grussenmeyer T; Schultze-Seemann W; Wetterauer U
Br J Cancer; 2000 Sep; 83(5):637-41. PubMed ID: 10944605
[TBL] [Abstract][Full Text] [Related]
14. [A study of effective administration of recombinant interferon-gamma in renal cell carcinoma regarding immunological influence on peripheral blood lymphocytes].
Kawata N; Ono M; Kodama M; Yamanaka Y; Hirakata H; Hirano D; Fuse T; Takimoto Y
Hinyokika Kiyo; 1995 Jan; 41(1):21-6. PubMed ID: 7900565
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy for renal cell carcinoma using IFN-gamma and OK-432: in vitro study.
Muraki J
Keio J Med; 1990 Mar; 39(1):21-5. PubMed ID: 2113148
[TBL] [Abstract][Full Text] [Related]
16. [Immunological study of the postoperative adjuvant treatment with interferon gamma in patients with renal cell cancer--measurement of peripheral blood lymphocyte subsets with three color flow cytometry].
Yasunaga Y; Nishimura K; Miura H; Takatera H; Kuroda H; Kishimoto T; Fujioka H
Hinyokika Kiyo; 1995 Feb; 41(2):85-92. PubMed ID: 7702012
[TBL] [Abstract][Full Text] [Related]
17. Role of low nuclear grading of renal carcinoma cells in the functional profile of tumor-infiltrating T cells.
Puccetti L; Manetti R; Parronchi P; Piccinni MP; Mavilia C; Carini M; Romagnani S; Maggi E
Int J Cancer; 2002 Apr; 98(5):674-81. PubMed ID: 11920635
[TBL] [Abstract][Full Text] [Related]
18. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
19. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the immune reactivity of infiltrating and peripheral lymphocytes from patients with renal cell carcinoma by measuring cytokine secretion.
Elsässer-Beile U; Wetterauer U; Schultze-Seemann W; Gallati H; Mönting JS; von Kleist S
Cancer Immunol Immunother; 1996 Feb; 42(2):93-8. PubMed ID: 8620526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
